

Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

Note: Transcatheter Uterine Artery Embolization is addressed separately in medical policy 00130.

Note: Magnetic Resonance-Guided Focused Ultrasound is addressed separately in medical policy 00180.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider laparoscopic or transcervical radiofrequency ablation (RFA) as a treatment of symptomatic uterine fibroids to be **eligible for coverage**** when **ALL** of the following conditions are met:

- Individual is 18 years or older; **AND**
- Evidence of uterine fibroids via ultrasound that are less than 10 cm in diameter for laparoscopic RFA with Acessa or less than 7 cm for transcervical RFA with Sonata; **AND**
- Individual desires a uterine-sparing treatment approach or is ineligible for hysterectomy or other uterine-sparing alternatives to RFA (e.g., laparoscopic myomectomy, uterine artery embolization [UAE]); **AND**
- Individual has experienced **ANY** of the following symptoms that are a direct result of the fibroid(s):
 - Menorrhagia or other abnormal uterine bleeding that interferes with daily activities or causes anemia;
 - *Note: In individuals greater than 45 years of age with menorrhagia or other abnormal bleeding, endometrial biopsy is recommended prior to treatment to rule out endometrial malignancy and/or additional assessment to rule out a risk for uterine leiomyosarcoma.*
 - Pelvic pain or pressure;

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

- Urinary symptoms (e.g., urinary frequency, urgency) related to bulk compression of the bladder;
 - Gastrointestinal symptoms related to bulk compression of the bowel (e.g., constipation, bloating);
 - Dyspareunia (painful or difficult sexual relations); **AND**
- Reintervention with RFA may be considered for individuals meeting policy criteria with documentation of new or recurrent fibroid development following a partial response with the initial procedure.

Note: Data on reinterventions for new or recurrent fibroids is limited.

When Services Are Considered Not Medically Necessary

The use of laparoscopic or transcervical radiofrequency ablation (RFA) as a treatment of symptomatic uterine fibroids when patient selection criteria are not met is considered to be **not medically necessary**.**

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers other laparoscopic, transcervical, or percutaneous techniques for myolysis of uterine fibroids, including use of laser or bipolar needles, cryomyolysis, and magnetic resonance imaging-guided laser ablation to be **investigational**.*

Policy Guidelines

Eligibility Considerations

Abnormal uterine bleeding refers to uterine bleeding of abnormal frequency, duration, and volume that interferes with an individual's quality of life. Individuals with abnormal uterine bleeding with an inadequate response to appropriately selected medical therapy may be considered for alternate uterine-sparing interventions.

Clinical trial experience with radiofrequency ablation (RFA) has been limited to patients with overall uterine size less than or equal to 16 gestational weeks size based on pelvic examination. In individuals where fibroids cannot be distinguished from adenomyosis on ultrasound, advanced imaging (e.g., magnetic resonance imaging [MRI]) may be required. For individuals with pelvic pain, alternative causes such as endometritis and active pelvic inflammatory disease should be excluded prior to treatment with RFA.

Treatment Approach Considerations for Radiofrequency Ablation

Uterine fibroids are categorized according to the International Federation of Gynaecology and Obstetrics (FIGO) leiomyoma subclassification system (see Table PG1). Choice of laparoscopic versus transcervical RFA treatment is dependent on fibroid number, size, type and location, and individual preferences. For example, predominantly lower uterine segment or cervical leiomyomata,

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

or those with a predominant submucosal location or intramural FIGO type 2 or 3 fibroids, may suggest a transcervical approach, whereas fibroids with largely fundal or extramural components may suggest a laparoscopic approach. Individuals aiming to avoid future deliveries via obligate cesarean section may prefer a transcervical approach. Select individuals with numerous fibroids may benefit from combined laparoscopic RFA and laparoscopic myomectomy. Individuals with intramural fibroids, intra-abdominal adhesions, or medical contraindications may not be candidates for alternative uterine-sparing interventions.

Table PG1. International Federation of Gynaecology and Obstetrics (FIGO) Leiomyoma Subclassification System

Group	Type	Description
Submucosal	0	Pedunculated intracavitary
	1	<50% intramural ($\geq$ 50% submucosal)
	2	$\geq$ 50% intramural (<50% submucosal)
Other	3	100% intramural, contacting endometrium
	4	100% intramural, no endometrial or subserosal contact
	5	Subserosal, $\geq$ 50% intramural
	6	Subserosal, <50% intramural
	7	Pedunculated subserosal
	8	Non-myometrial location (eg, cervical, broad ligament, parasitic)
Hybrid	X-X	Both submucosal and subserosal components. Submucosal component designated by first number and subserosal component designated by second number.

Table adapted from Gomez et al (2021). MRI-based pictorial review of the FIGO classification system for uterine fibroids. *Abdom Radiol*. 46(5): 2146-2155. PMID: 33385249.

Reinterventions

Reintervention with RFA may be considered for individuals meeting policy criteria with documentation of new or recurrent fibroid development following a partial response with the initial procedure. However, data on reinterventions for new or recurrent fibroids is limited and documentation procedures for repeat anatomic mapping of fibroids are not standardized.

Background/Overview

Uterine Fibroids

Uterine fibroids, also known as leiomyomas, are among the most common conditions affecting women in their reproductive years; symptoms include menorrhagia, pelvic pressure, or pain. It is estimated that uterine fibroids occur in up to 70% of women by menopause, with approximately 25% of these being clinically significant and requiring intervention. The prevalence rate of uterine

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

fibroids is 2 to 3 times higher among Black women compared with White women, and there are higher rates of hysterectomy and myomectomy compared with non-surgical therapy, potentially demonstrating a disparity in access to uterine-sparing interventions.

Treatment

Surgery, including hysterectomy and various myomectomy procedures, is considered the criterion standard for symptom resolution. However, there is the potential for surgical complications and, in the case of a hysterectomy, the uterus is not preserved. In addition, multiple myomectomies may be associated with longer operating time, postoperative febrile morbidity, and development of pelvic adhesions. There has been long-standing research interest in developing minimally invasive alternatives for treating uterine fibroids, including procedures that retain the uterus and permit future childbearing. Treatment options include uterine artery embolization and transcatheter magnetic resonance imaging-guided focused ultrasound therapy (see medical policy 00180). Various techniques to induce myolysis have also been studied including Nd:YAG lasers, bipolar electrodes, cryomyolysis, and radiofrequency ablation. With these techniques, an energy source is used to create areas of necrosis within uterine fibroids, reducing their volume and thus relieving symptoms. Early methods involved multiple insertions of probes into the fibroid, performed without imaging guidance. There were concerns about serosal injury and abdominopelvic adhesions with these techniques, possibly due to the multiple passes through the serosa needed to treat a single fibroid. Newer systems using radiofrequency energy do not require repetitive insertions of needle electrodes. Ultrasonography is used laparoscopically or transcervically to determine the size and location of fibroids, to guide the probe, and to ensure the probe is in the correct location so that optimal energy is applied to the fibroid. Percutaneous approaches using magnetic resonance imaging guidance have also been reported.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

In 2012, the Acessa^{TM†} System (Acessa Health, formerly Halt Medical) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for percutaneous laparoscopic coagulation and ablation of soft tissue and treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance (K121858). The technology was previously approved in 2010, at which time it was called the Halt 2000GI^{TM†} Electrosurgical Radiofrequency Ablation System. In 2014, the ultrasound guidance system received marketing clearance from the FDA (K132744). FDA product code: GEI. In 2018, the third-generation Acessa^{TM†} ProVu System^{®†} was cleared for marketing by the FDA through the 510(k) process for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. (K181124). Hologic acquired Accessa Health in 2020. FDA product code: HFG.

In 2018, the Sonata^{®†} Sonography-Guided Transcervical Fibroid Ablation System (Gynesonics) was cleared for marketing by the FDA through the 510(k) process for diagnostic intrauterine imaging and transcervical radiofrequency ablation as treatment of symptomatic uterine fibroids (K173703). The Sonata System 2.1 received marketing clearance in 2020 (K193516) and the Sonata System 2.2

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

received marketing clearance in 2021 (K211535). The Sonata system was previously known as Vizablate. FDA product codes: KNF, ITX, and IYO.

Cryoablation is a surgical procedure that uses previously approved and available cryoablation systems; and as a surgical procedure, it is not subject to regulation by the FDA. Other products addressed in this review (eg, Nd:YAG lasers, bipolar electrodes) have long-standing FDA approval, and there are no products specifically approved for the treatment of uterine fibroids.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

Description

Various minimally invasive treatments for uterine fibroids have been proposed as alternatives to surgery. Among these approaches are laparoscopic, percutaneous, and transcervical techniques to induce myolysis, which includes radiofrequency ablation (RFA), laser and bipolar needles, cryomyolysis, and magnetic resonance imaging-guided laser ablation.

Summary of Evidence

For individuals who have symptomatic uterine fibroids who receive radiofrequency ablation (RFA), the evidence includes prospective cohorts, randomized controlled trials (RCTs), and systematic reviews. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. The meta-analyses found low rates of reintervention with RFA and quality of life outcomes that were similar to uterine artery embolization and myomectomy at 12 months. Data on reintervention rates at 36 months were limited to 1 RCT and 1 cohort study with high loss to follow-up. No studies reported reintervention rates at 60 months. Two RCTs found that RFA was noninferior and one RCT found that RFA was superior to laparoscopic myomectomy on the primary outcome: length of hospitalization. A number of secondary outcomes were reported at 12 or 24 months in 2 RCTs, including symptoms and quality of life. One RCT found that both symptoms and quality of life were significantly better with myomectomy compared with RFA at 12 months. The procedure has faster recovery than myomectomy, and provides a reduction in symptoms and improvement in quality of life in the short term. Recurrence and reintervention rates at longer follow-up are unknown. Well-designed comparative trials with longer follow-up are needed to determine the effect of RFA on health outcomes compared with other treatment options such as myomectomy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have symptomatic uterine fibroids who receive laser or bipolar needles, the evidence includes case series. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. The case series were published in the 1990s, and the procedures used then may not reflect current practice. RCTs comparing laser or bipolar needles with alternative treatments for

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

uterine fibroids are needed to evaluate the safety and efficacy of this technology adequately. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have symptomatic uterine fibroids who receive cryomyolysis, the evidence includes case series. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. Among the few case series, sample sizes were small (≤ 20 patients). RCTs comparing cryomyolysis with alternative treatments for uterine fibroids are needed to evaluate the safety and efficacy of this technology adequately. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have symptomatic uterine fibroids who receive magnetic resonance imaging (MRI)-guided laser ablation, the evidence includes a study with historical controls. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. A single study with historical controls is not sufficiently robust to evaluate this technology. RCTs comparing MRI-guided laser ablation with alternative treatments for uterine fibroids are needed to evaluate safety and efficacy adequately. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2021 Input

Clinical input was sought to help determine whether the use of laparoscopic or transcervical radiofrequency ablation (RFA) for individuals with symptomatic uterine fibroids would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input on the use of RFA was received from 3 respondents, including: 1 society-level response including input from physicians affiliated with academic medical centers and 2 physician-level responses with academic affiliations.

For individuals with symptomatic uterine fibroids, clinical input provides consistent support that the use of laparoscopic or transcervical RFA provides a clinically meaningful improvement in the net health outcome and is consistent with generally accepted medical practice for the following indication:

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

Women 18 years and older when ALL of the following conditions are met:

- Evidence of uterine fibroids via ultrasound that are less than 10 cm in diameter for laparoscopic RFA with Acessa or 7 cm for transcervical RFA with Sonata; AND
- Patient desires a uterine-sparing treatment approach or is contraindicated for hysterectomy or other uterine-sparing alternatives to RFA (e.g., laparoscopic myomectomy, uterine artery embolization [UAE]); AND
- Patient has experienced at least 1 of the following symptoms that are a direct result of the fibroid(s):
 - Menorrhagia or other abnormal uterine bleeding that interferes with daily activities or causes anemia;
 - Pelvic pain or pressure;
 - Urinary symptoms (e.g., urinary frequency, urgency) related to bulk compression of the bladder;
 - Gastrointestinal symptoms related to bulk compression of the bowel (e.g., constipation, bloating);
 - Dyspareunia (painful or difficult sexual relations).

Respondents noted that choice of laparoscopic versus transcervical RFA treatment is dependent on fibroid number, type and location, and patient preferences. For example, predominantly lower uterine segment or cervical leiomyomata, or those with a predominant submucosal location or intramural International Federation of Gynecology and Obstetrics (FIGO) type 2 or 3 fibroids (see Table PG1), may suggest a transcervical approach, whereas fibroids with largely fundal or extramural components may suggest a laparoscopic approach.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Obstetricians and Gynecologists

In 2021, the American College of Obstetricians and Gynecologists updated its practice bulletin on the management of symptomatic leiomyomas. Recommendations based on a review of evidence included the following:

- Radiofrequency ablation can be considered as a minimally invasive treatment option in patients who desire to retain their uterus, provided they are counseled about the limited data on reproductive outcomes. Laparoscopic, transvaginal, or transcervical approaches using ultrasound guidance are considered similarly effective.
- Focused ultrasound is associated with a reduction in leiomyoma and uterine size, but is associated with less improvement in symptoms and quality of life and a higher risk of reintervention compared with uterine artery embolization.

Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

- Myomectomy was recommended as an option in patients who desire uterine preservation or future pregnancy and are counseled about the risk of recurrence. The laparoscopic approach is associated with shorter hospitalization, less postoperative pain, faster return to work, and earlier return to normal activities.
- Hysterectomy is recommended as a definitive surgical management option in patients who do not desire future childbearing or do not wish to retain their uterus.

This bulletin was reaffirmed in 2025.

National Institute for Health and Care Excellence

In 2021, NICE published an interventional procedures guidance on the use of transcervical ultrasound-guided RFA for symptomatic uterine fibroids. The NICE guidance noted that while evidence on the safety of transcervical RFA raises no major safety concerns, evidence on the efficacy of the procedure is limited in quality. Therefore, NICE recommends that the procedure should only be used with special arrangements for clinical governance, consent, and audit or research.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this medical policy are listed in Table 1.

Table 1. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT02100904	Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry (ULTRA Registry)	578	Jan 2026

NCT: national clinical trial.

^a Denotes industry-sponsored or cosponsored trial.

References

1. Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228. Obstet Gynecol. Jun 01 2021; 137(6): e100-e115. PMID 34011888
2. Laughlin-Tommaso SK, Jacoby VL, Myers ER. Disparities in Fibroid Incidence, Prognosis, and Management. Obstet Gynecol Clin North Am. Mar 2017; 44(1): 81-94. PMID 28160895

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

3. Stewart EA, Nicholson WK, Bradley L, et al. The burden of uterine fibroids for African-American women: results of a national survey. *J Womens Health (Larchmt)*. Oct 2013; 22(10): 807-16. PMID 24033092
4. Jones S, O'Donovan P, Toub D. Radiofrequency ablation for treatment of symptomatic uterine fibroids. *Obstet Gynecol Int*. 2012; 2012: 194839. PMID 21961009
5. Davis MR, Soliman AM, Castelli-Haley J, et al. Reintervention Rates After Myomectomy, Endometrial Ablation, and Uterine Artery Embolization for Patients with Uterine Fibroids. *J Womens Health (Larchmt)*. Oct 2018; 27(10): 1204-1214. PMID 30085898
6. Sandberg EM, Tummers FHMP, Cohen SL, et al. Reintervention risk and quality of life outcomes after uterine-sparing interventions for fibroids: a systematic review and meta-analysis. *Fertil Steril*. Apr 2018; 109(4): 698-707.e1. PMID 29653718
7. Havryliuk Y, Setton R, Carlow JJ, et al. Symptomatic Fibroid Management: Systematic Review of the Literature. *JSLs*. 2017; 21(3). PMID 28951653
8. Lin L, Ma H, Wang J, et al. Quality of Life, Adverse Events, and Reintervention Outcomes after Laparoscopic Radiofrequency Ablation for Symptomatic Uterine Fibroids: A Meta-Analysis. *J Minim Invasive Gynecol*. 2019; 26(3): 409-416. PMID 30253997
9. Bradley LD, Pasic RP, Miller LE. Clinical Performance of Radiofrequency Ablation for Treatment of Uterine Fibroids: Systematic Review and Meta-Analysis of Prospective Studies. *J Laparoendosc Adv Surg Tech A*. Dec 2019; 29(12): 1507-1517. PMID 31702440
10. Arnreiter C, Oppelt P. A Systematic Review of the Treatment of Uterine Myomas Using Transcervical Ultrasound-Guided Radiofrequency Ablation with the Sonata System. *J Minim Invasive Gynecol*. Aug 2021; 28(8): 1462-1469. PMID 33892184
11. Zhang J, Go VA, Blanck JF, et al. A Systematic Review of Minimally Invasive Treatments for Uterine Fibroid-Related Bleeding. *Reprod Sci*. Oct 2022; 29(10): 2786-2809. PMID 34480321
12. Chen I, Berman JM, Balk EM, et al. Radiofrequency Ablation for the Treatment of Uterine Fibroids: A Systematic Review and Meta-Analysis by the AAGL Practice Committee. *J Minim Invasive Gynecol*. Jan 2025; 32(1): 74-91. PMID 39277104
13. Dominoni M, Gardella B, Gritti A, et al. Conservative Treatment of Uterine Myomas: A Network Meta-Analysis of Randomized Controlled Studies. *J Minim Invasive Gynecol*. Jul 2025; 32(7): 583-591.e1. PMID 39733851
14. Brucker SY, Hahn M, Kraemer D, et al. Laparoscopic radiofrequency volumetric thermal ablation of fibroids versus laparoscopic myomectomy. *Int J Gynaecol Obstet*. Jun 2014; 125(3): 261-5. PMID 24698202
15. Rattray DD, Weins L, Regush LC, et al. Clinical outcomes and health care utilization pre- and post-laparoscopic radiofrequency ablation of symptomatic fibroids and laparoscopic myomectomy: a randomized trial of uterine-sparing techniques (TRUST) in Canada. *Clinicoecon Outcomes Res*. 2018; 10: 201-212. PMID 29670382
16. Yu S, Silverberg K, Bhagavath B, et al. Post-Market Safety of Laparoscopic Ultrasound-Guided Radiofrequency Ablation. *JSLs*. 2020; 24(4). PMID 33510567
17. Yu S, Bhagavath B, Shobeiri SA, et al. Clinical and Patient Reported Outcomes of Pre- and Postsurgical Treatment of Symptomatic Uterine Leiomyomas: A 12-Month Follow-up Review of TRUST, a Surgical Randomized Clinical Trial Comparing Laparoscopic Radiofrequency Ablation and Myomectomy. *J Minim Invasive Gynecol*. Jun 2022; 29(6): 726-737. PMID 35085837

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

18. Hahn M, Brucker S, Kraemer D, et al. Radiofrequency Volumetric Thermal Ablation of Fibroids and Laparoscopic Myomectomy: Long-Term Follow-up From a Randomized Trial. *Geburtshilfe Frauenheilkd.* May 2015; 75(5): 442-449. PMID 26097247
19. Krämer B, Hahn M, Taran FA, et al. Interim analysis of a randomized controlled trial comparing laparoscopic radiofrequency volumetric thermal ablation of uterine fibroids with laparoscopic myomectomy. *Int J Gynaecol Obstet.* May 2016; 133(2): 206-11. PMID 26892690
20. Berman JM, Guido RS, Garza Leal JG, et al. Three-year outcome of the Halt trial: a prospective analysis of radiofrequency volumetric thermal ablation of myomas. *J Minim Invasive Gynecol.* 2014; 21(5): 767-74. PMID 24613404
21. Berman JM, Bradley L, Hawkins SM, et al. Uterine Fibroids in Black Women: A Race-Stratified Subgroup Analysis of Treatment Outcomes After Laparoscopic Radiofrequency Ablation. *J Womens Health (Larchmt).* Apr 2022; 31(4): 593-599. PMID 34287028
22. Jacoby VL, Parvataneni R, Oberman E, et al. Laparoscopic Radiofrequency Ablation of Uterine Leiomyomas: Clinical Outcomes during Early Adoption into Surgical Practice. *J Minim Invasive Gynecol.* 2020; 27(4): 915-925. PMID 31376584
23. Miller CE, Osman KM. Transcervical Radiofrequency Ablation of Symptomatic Uterine Fibroids: 2-Year Results of the SONATA Pivotal Trial. *J Gynecol Surg.* Dec 01 2019; 35(6): 345-349. PMID 32226268
24. Lukes A, Green MA. Three-Year Results of the SONATA Pivotal Trial of Transcervical Fibroid Ablation for Symptomatic Uterine Myomata. *J Gynecol Surg.* Oct 01 2020; 36(5): 228-233. PMID 33061253
25. Brölmann H, Bongers M, Garza-Leal JG, et al. The FAST-EU trial: 12-month clinical outcomes of women after intrauterine sonography-guided transcervical radiofrequency ablation of uterine fibroids. *Gynecol Surg.* 2016; 13: 27-35. PMID 26918001
26. Shifrin G, Engelhardt M, Gee P, et al. Transcervical fibroid ablation with the Sonata™ system for treatment of submucous and large uterine fibroids. *Int J Gynaecol Obstet.* Oct 2021; 155(1): 79-85. PMID 33544889
27. Christoffel L, Römer T, Schiermeier S. Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE): Study Protocol and Preliminary Results. *Med Devices (Auckl).* 2021; 14: 77-84. PMID 33688276
28. Keltz J, Levie M, Chudnoff S. Pregnancy Outcomes After Direct Uterine Myoma Thermal Ablation: Review of the Literature. *J Minim Invasive Gynecol.* 2017; 24(4): 538-545. PMID 28109894
29. Polin M, Hur HC. Radiofrequency Ablation of Uterine Myomas and Pregnancy Outcomes: An Updated Review of the Literature. *J Minim Invasive Gynecol.* Jun 2022; 29(6): 709-715. PMID 35123041
30. Berman JM, Shashoua A, Olson C, et al. Case Series of Reproductive Outcomes after Laparoscopic Radiofrequency Ablation of Symptomatic Myomas. *J Minim Invasive Gynecol.* 2020; 27(3): 639-645. PMID 31238151
31. Christoffel L, Bends R, Toub D, et al. Pregnancy Outcomes After Transcervical Radiofrequency Ablation of Uterine Fibroids with the Sonata System. *J Gynecol Surg.* Jun 01 2022; 38(3): 207-213. PMID 35785107
32. Hansen-Lindner L, Schmid-Lossberg J, Toub D. Transcervical Fibroid Ablation (TFA): Update on Pregnancy Outcomes. *J Clin Med.* May 14 2024; 13(10). PMID 38792434

Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

33. Allen A, Schembri M, Parvataneni R, et al. Pregnancy Outcomes After Laparoscopic Radiofrequency Ablation of Uterine Leiomyomas Compared With Myomectomy. *Obstet Gynecol*. May 01 2024; 143(5): 612-618. PMID 38422502
34. Goldfarb HA. Bipolar laparoscopic needles for myoma coagulation. *J Am Assoc Gynecol Laparosc*. Feb 1995; 2(2): 175-9. PMID 9050553
35. Goldfarb HA. Nd:YAG laser laparoscopic coagulation of symptomatic myomas. *J Reprod Med*. Jul 1992; 37(7): 636-8. PMID 1387912
36. Nisolle M, Smets M, Malvaux V, et al. Laparoscopic myolysis with the Nd:YAG laser. *J Gynecol Surg*. 1993; 9(2): 95-9. PMID 10171973
37. Donnez J, Squifflet J, Polet R, et al. Laparoscopic myolysis. *Hum Reprod Update*. 2000; 6(6): 609-13. PMID 11129695
38. Phillips DR, Nathanson HG, Milim SJ, et al. Laparoscopic Leiomyoma Coagulation. *J Am Assoc Gynecol Laparosc*. Aug 1996; 3(4, Supplement): S39. PMID 9074213
39. Zreik TG, Rutherford TJ, Palter SF, et al. Cryomyolysis, a new procedure for the conservative treatment of uterine fibroids. *J Am Assoc Gynecol Laparosc*. Feb 1998; 5(1): 33-8. PMID 9454874
40. Zupi E, Piredda A, Marconi D, et al. Directed laparoscopic cryomyolysis: a possible alternative to myomectomy and/or hysterectomy for symptomatic leiomyomas. *Am J Obstet Gynecol*. Mar 2004; 190(3): 639-43. PMID 15041993
41. Zupi E, Marconi D, Sbracia M, et al. Directed laparoscopic cryomyolysis for symptomatic leiomyomata: one-year follow up. *J Minim Invasive Gynecol*. 2005; 12(4): 343-6. PMID 16036195
42. Hindley JT, Law PA, Hickey M, et al. Clinical outcomes following percutaneous magnetic resonance image guided laser ablation of symptomatic uterine fibroids. *Hum Reprod*. Oct 2002; 17(10): 2737-41. PMID 12351555
43. National Institute for Health and Care Excellence (NICE). Interventional procedures guidance: Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids [IPG689]. March 31, 2021; <https://www.nice.org.uk/guidance/ipg689>.

Policy History

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

09/04/2014	Medical Policy Committee review
09/17/2014	Medical Policy Implementation Committee approval. New policy.
08/03/2015	Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
09/03/2015	Medical Policy Committee review
09/23/2015	Medical Policy Implementation Committee approval. No change to coverage.
01/01/2016	Coding update
09/08/2016	Medical Policy Committee review
09/21/2016	Medical Policy Implementation Committee approval. No change to coverage.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes and CPT coding update
10/05/2017	Medical Policy Committee review

Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

10/18/2017	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/04/2018	Medical Policy Committee review
10/17/2018	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/03/2019	Medical Policy Committee review
10/09/2019	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/01/2020	Medical Policy Committee review
10/07/2020	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/05/2021	Medical Policy Committee review
08/11/2021	Medical Policy Implementation Committee approval. Replaced the investigational statement with an eligible for coverage with criteria statement for ultrasound-guided radiofrequency ablation for the treatment of uterine fibroids. Added an investigational statement for all other techniques of myolysis as a treatment of uterine fibroids.
08/04/2022	Medical Policy Committee review
08/10/2022	Medical Policy Implementation Committee approval. Title changed from “Laparoscopic and Percutaneous Techniques for the Myolysis of Uterine Fibroids” to “Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis”. Revised the entire coverage section.
08/03/2023	Medical Policy Committee review
08/09/2023	Medical Policy Implementation Committee approval. Replaced “Patient” with “Individual” in the Patient Selection Criteria. Coverage eligibility unchanged.
12/12/2023	Coding update
08/01/2024	Medical Policy Committee review
08/14/2024	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/07/2025	Medical Policy Committee review
08/13/2025	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/06/2026	Medical Policy Committee review
08/12/2026	Medical Policy Implementation Committee review
08/20/2026	Medical Quality Management Committee approval. Changed the use of laparoscopic or transcervical radiofrequency ablation (RFA) as a treatment of symptomatic uterine fibroids when patient selection criteria are not met from investigational to not medically necessary. Moved the last sentence from the Policy Guidelines to a <i>Note</i> in the criteria for symptoms that are a direct result of the fibroid(s). Coverage eligibility unchanged.

Next Scheduled Review Date: 08/2027

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

Coding

The five character codes included in the Louisiana Blue Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2025 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Louisiana Blue Medical Policy Coverage Guidelines is with Louisiana Blue and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Louisiana Blue Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Louisiana Blue Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	58578, 58580, 58674, 58999, 76940, 77022
HCPCS	No codes
ICD-10 Diagnosis	D25.0-D25.9

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);

Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis

Policy # 00445

Original Effective Date: 09/17/2014

Current Effective Date: 09/01/2026

2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan’s authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan’s pharmacy benefit.